Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01245816
Other study ID # CPP FAP-301
Secondary ID
Status Withdrawn
Phase Phase 3
First received November 19, 2010
Last updated April 23, 2015
Start date March 2011
Est. completion date June 2013

Study information

Verified date April 2015
Source Cancer Prevention Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this phase III study is to evaluate the safety and efficacy of the combination of eflornithine and sulindac compared to single agent sulindac or eflornithine in reducing the number of polyps in patients with familial adenomatous polyposis (FAP).


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2013
Est. primary completion date May 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Diagnosis of phenotypic Familial Adenomatous Polyposis (FAP) of the colorectum based on meeting the criteria in one of two groups: Group 1-Greater than 100 adenomatous colorectal polyps prior to age 40. Group 2-Greater than 10 adenomatous polyps and age <40 or greater than 25 polyps and age >40; combined with a dominant family history or genotype: More than 100 polyps in a first-degree relative; More than 25 polyps in 2 relatives in 2 generations, including a first-degree family member; Genetic diagnosis in a relative; Genetic diagnosis by in vitro synthesized truncated protein or similar assay.

- No colorectal surgery or prior colon surgery for polyposis at least 1 year prior (total abdominal colectomy with ileal-rectal anastomosis, or total proctocolectomy with ilea pouch-anal reconstruction.

- Baseline endoscopy

1. If no prior colorectal surgery, at least 3 polyps in a cluster each = 2 mm in diameter; or

2. If rectum is in situ and to be assessed, baseline rectal segment endoscopy documenting 3 or more rectal polyps each at least 2 mm in diameter in a defined cluster and/or at least 6 polyps, = 2 mm in diameter, in the distal 10 cm of rectum

3. If ileal pouch neo-rectum is in place, 3 or more pouch polyps in a cluster = 2 mm in diameter, or at least 6 polyps, = 2 mm in diameter, in the distal 10 cm of pouch.

4. Clinical/pathological grading of duodenal polyps will utilize the Spigelman Classification.

- Hematopoietic: no significant hematologic dysfunction; WBC =3,000/mm3; platelet count =100,000/mm3; hemoglobin =10g/dL; no known or prior clinical coagulopathy.

- Hepatic: bilirubin = 1.5 times ULN; AST and ALT = 1.5 times ULN; Alkaline phosphatase = 1.5 times ULN.

- Renal: No significant renal dysfunction; creatinine = 1.5 times ULN.

- Hearing: no clinically significant hearing loss that affects everyday life.

- Not pregnant or nursing.

- Negative serum pregnancy test if female of child-bearing potential.

- Absence of gross blood in stool.

- Fertile patients must use effective contraception.

- Stool occult blood either negative or minimal (1+).

- No prior hypersensitivity to cyclooxygenase-2 inhibitors, sulfonamides, NSAIDs, or salicylates; no NSAID associated symptoms of gastritis.

- No discrete gastric or duodenal ulcer greater than 5 mm within the past year except Helicobacter pylori-related peptic ulcer disease treated successfully with antibiotics (as documented by an endoscopy.

- No invasive malignancy within the past 5 years except stage I or II colon or rectal cancer or resected nonmelanomatous skin cancer.

- No other significant medical or psychiatric problems that would preclude study participation.

- No chronic adrenocorticosteroids.

- No prior pelvic irradiation.

- At least 3 months since prior investigational agents.

- Patients may not be receiving or plan to receive corticosteroids.

- Concomitant NSAID use outside this study may not exceed 4 days per month.

- Use of 81 mg daily aspirin or 650 mg aspirin not more than once a week.

- No concurrent warfarin, fluconazole, or lithium.

- Must be willing and able to sign informed consent.

Exclusion Criteria:

- High Risk for cardiovascular disease including clinical diabetes mellitus (Type I or II) requiring glycemic medications; Prior personal history of cardiovascular disease or, two or more of the following - hypertension or use of anti-hypertensive medications, hyperlipidemia or use of lipid-lowering medications or current smoker.

- Hearing loss that affects everyday life and or for which a hearing aid is required.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Intervention

Drug:
Eflornithine plus Sulindac
Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
Eflornithine plus Placebo
Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
Sulindac plus Placebo
Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Cancer Prevention Pharmaceuticals, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of Eflornithine plus Sulindac compared to Eflornithine alone and Sulindac alone determined by change in the number of polyps 2 mm or greater in a defined focal area of the rectum or pouch at baseline and after completion of the study treatment. 6 months from the start of treatment. No
Secondary Change in number of polyps 2 mm or greater in the distal 10 cm of rectum or pouch. 6 months from the start of treatment. No
Secondary Qualitative change in overall colon/rectum/pouch polyp burden (number and size). 6 months from the start of treatment. No
Secondary Presence of high grade dysplasia or villous adenoma in any polyp resected. 6 months from the start of treatment. No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05630794 - Testing ONC201 to Prevent Colorectal Cancer Phase 1
Completed NCT02961374 - Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer Phase 2
Completed NCT01483144 - Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Phase 3
Completed NCT00641147 - Curcumin in Treating Patients With Familial Adenomatous Polyposis Phase 2
Recruiting NCT03471403 - Cold Snare Polypectomy for Duodenal Adenomas in Familial Adenomatous Polyposis
Not yet recruiting NCT04531930 - Colorectal Adenoma Canceration in FAP
Recruiting NCT04677998 - A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis
Recruiting NCT04678011 - A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy
Completed NCT00927485 - Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP) N/A
Recruiting NCT00253812 - Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy N/A
Withdrawn NCT00248053 - Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients Phase 2
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Completed NCT04674228 - Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01
Completed NCT01656746 - Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease N/A
Completed NCT00808743 - Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Phase 2/Phase 3
Active, not recruiting NCT03847636 - CryoBalloon Ablation for Treatment of Duodenal Adenomas N/A
Not yet recruiting NCT05112822 - Testing Obeticholic Acid (OCA) for Familial Adenomatous Polyposis (FAP) Phase 1
Recruiting NCT02656134 - Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP) N/A
Recruiting NCT04709445 - Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses N/A
Enrolling by invitation NCT05402891 - The CHAMP-study: The CHemopreventive Effect of Lithium in Familial AdenoMatous Polyposis Phase 2